Table 1.
Summary
| Timepoint | Enrolment | Post-allocation * denotes 3-h intervals |
Follow-up | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before infusion | 1 h | 2 h | 3 h | 6 h | * | 12 h | * | 24 h | * |
36 h |
* | 48 h | 3 months | |
| Enrolment | ||||||||||||||
| Eligibility screen | X | |||||||||||||
| Informed consent | X | |||||||||||||
| Randomization | X | |||||||||||||
| Interventions | ||||||||||||||
| Tocilizumab 280 mg/placebo | X | |||||||||||||
| Assessments | ||||||||||||||
| Arterial puncture (lactate, blood glucose) | X | |||||||||||||
| proBNP, biomarkers, biobank | X | X | X | X | X | X | ||||||||
| CMR | X | X | ||||||||||||
| TTE | X | X | X | |||||||||||
| 12-lead ECG | X | X | X | X | X | |||||||||
| Telemetry | X | |||||||||||||
| BP, P, RR, SAT, Tp | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| QoL, MoCA, GS, frailty | X | X | ||||||||||||
Abbreviations: h Hour, proBNP Pro-B-type natriuretic peptide, CMR Cardiac magnetic resonance, TTE Transthoracic echocardiography, ECG Electrocardiography, BP Blood Pressure, P Pulse, RR Respiratory Rate, Tp Temperature, QoL Quality of life, MoCA Montreal Cognitive Assessment, GS Grip strength